Hematology

The assistant professor of Hematologic Oncology and Blood Disorders at Atrium Health discussed integrating CAR T therapy into treatment paradigms.

Review top news and interview highlights from the week ending November 4, 2022.

Data from the first 2 patients were presented at the IWWM 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

MT-101 is designed for quick delivery to patients with a vein-to-vein time of 8 days.

The medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.

Shah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Cells produced by this method were also shown to be more potent in animal models than cells made with typical processes.

As we learn more about genomics and identify more genes tied to rare disorders, the role of genetic counselors will become even more critical.

The senior vice president of Research & Early Development at Notch Therapeutics discussed the company’s approach to overcoming the drawbacks of autologous cell therapies.

The decision comes after a previous clinical hold delayed key medical milestones in the KEYNOTE-B79 trial.

The medical oncologists at Washington University School of Medicine in St. Louis discussed background to their research on associations between neurofilament light and neurotoxicity.

Review top news and interview highlights from the week ending October 21, 2022.

The first 6 patients dosed in the ANTLER trial had a 50% CR rate at 6 months.

Pam Gavin, executive vice president of NORD, discussed actions the organization is taking to further improve access to advanced care.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The executive director of Hemophilia Foundation Southern California discussed issues with minorities accessing care for rare diseases and strategies to mitigate them.

The approval was based on data from ZUMA-7, a phase 3 clinical trial.

With so many therapies on the horizon, the clinical and patient communities need to be adequately prepared to support them.

The first patient has been dosed in a phase 2 study of the allogeneic CAR T-cell therapy GC007g.

The director of translational research in myeloma at the Tisch Cancer Institute discussed positive findings, including a 30-month PFS in study participants.

Review top news and interview highlights from the week ending October 14, 2022.

The chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.

The PDUFA target date is set for March 31, 2023.